Detail akcie MannKind Rg online

Business Summary: MannKind Corporation is focused on the development and commercialization of inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The Company's technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices. In its endocrine business unit, it commercializes two products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its pipeline products include Pediatric Afrezza (insulin human) Inhalation Powder, MNKD-101 and MNKD-201.
Financial Summary: BRIEF: For the three months ended 31 March 2025, MannKind Corp revenues increased 18% to $78.4M. Net income increased 24% to $13.2M. Revenues reflect Royalties segment increase of 32% to $30M, Product sales segment increase of 11% to $47.8M, Services segment increase of 45% to $558K. Net income benefited from United States segment income increase of 33% to $22.3M. Basic Earnings per Share excluding Extraordinary Items remained flat at $0.04.